查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1550363

合成血液替代品市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、應用、來源、成分、地區和競爭細分，2019-2029F

Synthetic Blood Substitute Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Source, By Component, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023年全球合成血液替代品市場價值為861萬美元，預計2029年將達到1,504萬美元，預測期內複合年成長率為9.92%。

市場概況
預測期 2025-2029
2023 年市場規模 861萬美元
2029 年市場規模 1504萬美元
2024-2029 年複合年成長率 9.92%
成長最快的細分市場 心血管疾病
最大的市場 北美洲

全球合成血液替代品市場是一個快速發展的行業，專注於開發人造血液產品以解決傳統輸血的限制。合成血液替代品旨在克服血液短缺、交叉污染風險和相容性問題等挑戰。這些產品旨在執行人體血液的基本功能，例如氧氣運輸和營養物質輸送，並具有更高的安全性和更長的保存期限。該市場是由生物技術的進步以及由於需要輸血的創傷、手術和慢性疾病的發生率不斷增加而對替代品的需求不斷成長所推動的。例如，根據世界衛生組織癌症機構國際癌症研究機構 (IARC) 的數據，2022 年全球癌症負擔包括估計 2,000 萬新病例和 970 萬人死亡。此外，有 5,350 萬人在癌症診斷後五年內還活著。大約五分之一的人在一生中患有癌症，其中大約九分之一的男性和十二分之一的女性死於該疾病。

研究和開發工作的重點是創造基於血紅蛋白的氧載體（HBOC）和全氟化碳（PFC），這是合成血液替代品的兩大類。 HBOC 源自於改良血紅蛋白，旨在有效攜帶和釋放氧氣，而化學合成的 PFC 則可促進低氧環境中的氧氣運輸。市場上製藥公司、政府和研究機構正在進行大量投資，旨在解決安全問題並提高這些產品的功效。法規核准和臨床試驗在塑造市場格局方面發揮著至關重要的作用，各種產品處於不同的開發階段。公眾意識的提高和醫療保健基礎設施的改善正在促進市場的成長。

主要市場促進因素

外傷發生率增加

傳統輸血的局限性

對合成血液製品的認知與接受度不斷提高

主要市場挑戰

生產成本高

臨床數據有限且療效不確定

主要市場趨勢

生物技術的技術進步

新興市場對血液製品的需求不斷成長

細分市場洞察

產品洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球合成血液替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（血紅素載氧體 (HBOC)、全氟化碳乳劑 (PFC)、幹細胞衍生紅血球等）
    • 依應用（心血管疾病、惡性腫瘤、損傷、新生兒疾病、器官移植、孕產婦疾病、其他）
    • 依來源（人血、微生物為基礎的重組 HB、合成聚合物、幹細胞、其他）
    • 依成分（紅血球替代品、血小板替代品、血漿替代品）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖

第 6 章：北美合成血液替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按申請
    • 按來源
    • 按組件
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲合成血液替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按申請
    • 按來源
    • 按組件
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區合成血液替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按申請
    • 按來源
    • 按組件
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲合成血液替代品市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按申請
    • 按來源
    • 按組件
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲合成血液替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按申請
    • 按來源
    • 按組件
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Aurum Biosciences Ltd
  • Hemarina SA
  • Hemoglobin Oxygen Therapeutics LLC
  • SpheriTech Ltd
  • Kalocyte, Inc.
  • OPKO Health, Inc.
  • Prolong Pharmaceuticals, LLC
  • VisusMed Medical Center
  • Boston Pharmaceuticals, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 25000

Global Synthetic Blood Substitute Market was valued at USD 8.61 Million in 2023 and is expected to reach USD 15.04 Million by 2029 with a CAGR of 9.92% during the forecast period.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 8.61 Million
Market Size 2029USD 15.04 Million
CAGR 2024-20299.92%
Fastest Growing SegmentCardiovascular Diseases
Largest MarketNorth America

The global synthetic blood substitute market is a rapidly evolving sector focused on developing artificial blood products to address the limitations of conventional blood transfusions. Synthetic blood substitutes aim to overcome challenges such as blood shortages, cross-contamination risks, and compatibility issues. These products are designed to perform the essential functions of human blood, such as oxygen transport and nutrient delivery, with enhanced safety profiles and extended shelf lives. The market is driven by advancements in biotechnology and the growing need for alternatives due to the increasing incidence of traumatic injuries, surgeries, and chronic diseases that require blood transfusions. For instance, according to the World Health Organization's cancer agency, the International Agency for Research on Cancer (IARC), the global cancer burden in 2022 included an estimated 20 million new cases and 9.7 million deaths. Additionally, 53.5 million people were alive within five years of their cancer diagnosis. Approximately 1 in 5 individuals develop cancer during their lifetime, with about 1 in 9 men and 1 in 12 women dying from the disease.

Research and development efforts are focused on creating hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbons (PFCs), which are two major categories of synthetic blood substitutes. HBOCs are derived from modified hemoglobin and are designed to carry and release oxygen efficiently, while PFCs, which are chemically synthesized, facilitate oxygen transport in low-oxygen environments. The market is witnessing significant investments from pharmaceutical companies, governments, and research institutions, aiming to address safety concerns and improve the efficacy of these products. Regulatory approvals and clinical trials play a crucial role in shaping the market landscape, with various products at different stages of development. Increasing public awareness and healthcare infrastructure improvements are contributing to the market's growth.

Key Market Drivers

Increasing Incidence of Traumatic Injuries

The global synthetic blood substitute market is significantly propelled by the increasing incidence of traumatic injuries, which heightens the demand for blood products. Traumatic injuries, often resulting from accidents, natural disasters, or violent incidents, frequently lead to substantial blood loss that requires prompt and effective intervention. In such critical situations, the need for immediate blood transfusions becomes crucial. However, traditional blood supply systems can face limitations in addressing this urgent demand due to various challenges, such as difficulties in blood collection, storage issues, and the complexities of ensuring blood compatibility for transfusions.

Synthetic blood substitutes present a viable and advantageous alternative in these scenarios. Unlike real blood, which has a limited shelf life and poses risks of contamination, synthetic blood products are engineered to have extended shelf lives and reduced risk of infection. This makes them particularly valuable in emergency situations where rapid availability of blood is essential. These substitutes are designed to efficiently carry oxygen and perform vital functions that are necessary for sustaining life in the absence of real blood, thereby enhancing the effectiveness of emergency medical responses and improving patient outcomes.

The rise in traumatic injuries worldwide underscores the growing need for synthetic blood substitutes. As the frequency and severity of such injuries continue to increase, so does the reliance on these advanced products. This trend is driving market expansion, as healthcare systems seek more reliable and accessible solutions to manage blood shortages and ensure that critical care can be provided swiftly and safely.

Limitations of Conventional Blood Transfusions

Conventional blood transfusions face several inherent limitations that highlight the growing need for synthetic blood substitutes. In January 2022, the American Red Cross, responsible for distributing 40% of the nation's donor blood, declared an unprecedented national blood crisis as supplies, particularly the critical O-negative universal blood type, reached perilously low levels. Meanwhile, hemorrhagic shock from severe blood loss claims approximately 20,000 lives annually in the U.S. and 2 million globally. One of the primary issues is the limited shelf life of real blood. Blood products must be used within a specific timeframe to remain effective, which poses significant challenges in managing inventory and ensuring availability during emergencies. This limitation often leads to blood shortages, particularly in high-demand situations or remote areas. Another critical challenge is blood type compatibility. According to the WHO, in 54 countries, over 50% of the blood supply continues to rely on family/replacement and paid blood donors. This includes eight high-income countries, 36 middle-income countries, and 10 low-income countries. Each patient requires a blood transfusion that matches their specific blood type and Rh factor, which complicates the transfusion process and increases the risk of transfusion reactions. Ensuring compatibility requires extensive testing and can delay urgent transfusions, potentially impacting patient outcomes.

Conventional blood transfusions carry the risk of transfusion-related infections. Despite rigorous screening procedures, there remains a risk of transmitting infections such as hepatitis and HIV, which can have severe consequences for recipients. This risk underscores the need for safer alternatives that minimize the potential for infection transmission. Synthetic blood substitutes address these limitations by offering several advantages over traditional blood products. They have a significantly longer shelf life, allowing them to be stored and used more flexibly without the pressure of expiration. This extended usability helps mitigate the problem of blood shortages and ensures that blood products are available when needed.

Synthetic blood substitutes do not require blood type matching, simplifying the transfusion process and reducing the potential for compatibility issues. This not only accelerates the delivery of necessary care but also enhances patient safety by eliminating the risk of transfusion reactions related to blood type mismatches. Synthetic blood products are less susceptible to bacterial contamination compared to real blood, further improving safety for patients. By addressing these critical limitations, synthetic blood substitutes streamline transfusion practices, making them a more attractive option for healthcare providers and contributing to the growth of the market.

Growing Awareness and Acceptance of Synthetic Blood Products

Growing awareness and acceptance of synthetic blood products are pivotal factors driving the expansion of the market. As educational initiatives and public awareness campaigns become more prevalent, there is a significant increase in understanding regarding the benefits and potential of synthetic blood substitutes. These efforts are crucial in informing both healthcare professionals and patients about the advantages of synthetic alternatives compared to traditional blood products.

Synthetic blood substitutes offer several compelling benefits, including a reduced risk of disease transmission and improved availability. Unlike conventional blood, which can carry the risk of transmitting infectious diseases such as hepatitis and HIV, synthetic blood products are produced under controlled conditions and are free from these risks. This aspect alone is a significant advantage, as it addresses critical safety concerns associated with traditional blood transfusions. Synthetic blood substitutes have the advantage of longer shelf life and easier storage, which enhances their availability, especially in situations where traditional blood supply might be limited. This improved availability is particularly valuable in emergency situations or in regions with inadequate blood donation systems.

As awareness of these benefits grows, the acceptance of synthetic blood products is increasing. Healthcare professionals are becoming more informed about the potential of synthetic substitutes to improve patient outcomes and streamline medical practices. This growing acceptance is reflected in the increasing adoption of synthetic blood products in medical settings.Public awareness campaigns are also playing a crucial role in shaping perceptions and increasing the general acceptance of synthetic blood substitutes. By highlighting the advantages and safety features of these products, these campaigns are fostering a positive shift in public perception and encouraging their use.

Key Market Challenges

High Production Costs

High production costs pose a significant challenge to the global synthetic blood substitute market. The development of synthetic blood products involves advanced technologies and sophisticated manufacturing processes that contribute to their high cost. Producing synthetic blood substitutes requires specialized equipment, materials, and expertise, which can lead to substantial capital expenditures. The cost of research and development (R&D) is another major factor, as developing and refining synthetic blood products involves extensive testing, trials, and optimization.

The high production costs of synthetic blood substitutes can impact their affordability and accessibility. Healthcare systems and institutions, especially in low-resource settings, may find it challenging to afford these products, limiting their widespread adoption. This can result in uneven access to synthetic blood substitutes across different regions and healthcare settings. The high costs can restrict the market potential, as only a limited number of companies may be able to invest in the necessary technologies and resources for production. To address these cost-related challenges, companies are exploring strategies to optimize production processes and reduce expenses. This includes investing in more efficient manufacturing technologies, exploring cost-effective raw materials, and scaling up production to achieve economies of scale. Collaborations and partnerships with research institutions and other industry stakeholders can also help share the financial burden and drive innovation in cost reduction.

Limited Clinical Data and Uncertain Efficacy

The global synthetic blood substitute market faces challenges related to limited clinical data and uncertain efficacy. Despite significant advancements in synthetic blood technologies, the clinical evidence supporting the efficacy and safety of these products is still evolving. The effectiveness of synthetic blood substitutes in various medical applications must be thoroughly validated through clinical trials to gain widespread acceptance among healthcare professionals and regulatory bodies.

Limited clinical data can create uncertainty regarding the performance of synthetic blood substitutes in real-world scenarios. While preclinical studies and early-stage trials may demonstrate promising results, more extensive clinical research is needed to confirm their efficacy and safety across diverse patient populations and medical conditions. The lack of comprehensive clinical data can hinder the adoption of synthetic blood substitutes and impact their market acceptance.

Variations in clinical trial outcomes and study designs can contribute to uncertainty regarding the efficacy of synthetic blood products. Differences in trial methodologies, patient demographics, and treatment protocols can affect the interpretation of results and create variability in clinical evidence. This uncertainty can lead to reluctance among healthcare providers to adopt synthetic blood substitutes and may delay their integration into standard medical practices.

Key Market Trends

Technological Advancements in Biotechnology

Technological advancements in biotechnology are playing a pivotal role in driving the synthetic blood substitute market. Innovations across various fields, including genetic engineering, molecular biology, and material science, are fostering the development of increasingly effective and sophisticated synthetic blood products. These advancements are addressing the limitations of traditional blood substitutes and opening new avenues for improved blood replacement solutions. One notable area of progress is in hemoglobin-based oxygen carriers (HBOCs). Recent developments in this field have enhanced the ability of HBOCs to transport oxygen more efficiently, closely mimicking the function of natural hemoglobin in red blood cells. Enhanced stability and prolonged shelf life of these carriers have made them more viable for clinical use, addressing issues related to blood product storage and availability.

Similarly, advances in perfluorocarbons (PFCs) are revolutionizing synthetic blood substitutes. PFCs can dissolve and carry significant amounts of oxygen, even in the absence of red blood cells. Recent improvements in the formulation and delivery of PFCs have enhanced their biocompatibility and reduced the risks of adverse reactions, making them a more promising option for blood replacement and emergency transfusions. The ongoing investment by research institutions and pharmaceutical companies into these technologies reflects their commitment to overcoming existing limitations and advancing the functionality of synthetic blood products. Cutting-edge research is focused on optimizing the performance of synthetic substitutes, improving their safety profiles, and ensuring their effectiveness in diverse clinical scenarios.

These technological developments are expected to propel the synthetic blood substitute market by introducing products that offer superior oxygen-carrying capacity, enhanced stability, and greater biocompatibility. As these innovations continue to evolve, they will likely expand the applications of synthetic blood substitutes, driving market growth and offering new opportunities for improving patient care in critical situations.

Rising Demand for Blood Products in Emerging Markets

The increasing demand for blood products in emerging markets is a significant driver of the global synthetic blood substitute market. As healthcare infrastructure improves and populations expand in these regions, the need for effective and reliable blood transfusion solutions is growing. Emerging markets, which include developing countries in Asia, Africa, and Latin America, often encounter challenges such as inadequate blood donation rates and limited blood bank infrastructure. These issues frequently result in blood shortages, impacting the ability to provide timely and adequate medical care.

In these settings, synthetic blood substitutes present a valuable alternative to traditional blood products. Unlike conventional blood, which requires careful management and frequent replenishment, synthetic substitutes can be stored for extended periods and are less prone to contamination. This makes them an attractive option for regions where maintaining a steady and safe blood supply is difficult. Synthetic blood products can be produced in a controlled environment and do not rely on voluntary donations, addressing the issue of insufficient blood collection and storage.

As emerging economies continue to invest in healthcare infrastructure and expand their medical services, there is an increased emphasis on improving the availability and quality of medical supplies, including blood products. The adoption of synthetic blood substitutes aligns with these efforts by providing a reliable and scalable solution to meet the growing demand. This trend is further supported by governmental and non-governmental organizations working to enhance healthcare delivery in these regions. As emerging markets advance and healthcare systems develop, the role of synthetic blood substitutes is expected to become more prominent. The ability to offer a stable and dependable source of blood, without the limitations of traditional donation-based systems, is likely to drive market growth in these regions.

Segmental Insights

Product Insights

In 2023, Hemoglobin-Based Oxygen Carriers (HBOCs) emerged as the dominant segment in the global synthetic blood substitute market. This prominence is primarily due to their advanced development and demonstrated efficacy in oxygen transport. HBOCs, which are designed to mimic the oxygen-carrying function of natural hemoglobin, offer several advantages over other synthetic blood substitutes. One of the key factors driving the dominance of HBOCs is their ability to provide effective oxygen delivery even in challenging conditions. Unlike Perfluorocarbon Emulsions (PFCs), which have limitations related to oxygen solubility and require specific administration techniques, HBOCs can efficiently release oxygen to tissues and organs, making them highly suitable for critical medical situations. Their compatibility with a wide range of clinical applications, from trauma care to elective surgeries, further enhances their market position.

HBOCs have benefited from extensive research and clinical trials, establishing their safety and efficacy profiles. This robust clinical evidence has facilitated regulatory approvals and bolstered healthcare professionals' confidence in using these products. In contrast, Perfluorocarbon Emulsions, while promising, face challenges related to their complex metabolism and potential side effects.

Application Insights

In 2023, Cardiovascular Diseases emerged as the dominant application segment in the global synthetic blood substitute market. This prominence is attributed to the significant and growing need for effective blood substitutes in managing cardiovascular conditions, which frequently require substantial blood volume replacement and oxygenation support.

Cardiovascular diseases often necessitate complex surgical interventions, such as coronary artery bypass grafting (CABG), heart valve replacements, and other procedures that involve significant blood loss. Synthetic blood substitutes are critical in these scenarios due to their ability to provide reliable oxygen delivery and maintain blood volume, which is essential for successful surgical outcomes and patient recovery. The advanced performance of Hemoglobin-Based Oxygen Carriers (HBOCs) and Perfluorocarbon Emulsions (PFCs) in these settings has been a key factor driving their adoption. The increasing prevalence of cardiovascular diseases globally amplifies the demand for effective blood substitutes. As the incidence of heart disease rises, there is a greater need for innovative solutions that can address the challenges of traditional blood transfusions, such as limited availability and compatibility issues.

Regional Insights

In 2023, North America emerged as the dominated region in the global synthetic blood substitute market, holding the largest market share. North America boasts a highly advanced healthcare infrastructure, with extensive research and development capabilities. The region is home to numerous leading pharmaceutical and biotechnology companies that are actively engaged in the development and commercialization of synthetic blood substitutes. This robust R&D environment facilitates rapid innovation and the introduction of cutting-edge synthetic blood products.

The high prevalence of cardiovascular diseases, trauma cases, and elective surgeries in North America drives substantial demand for synthetic blood substitutes. The region's well-established healthcare system frequently encounters situations where synthetic blood products are essential for managing blood loss and enhancing patient outcomes. This ongoing demand contributes to North America's dominant market position.

Key Market Players

Aurum Biosciences Ltd

Hemarina SA

Hemoglobin Oxygen Therapeutics LLC

SpheriTech Ltd

Kalocyte, Inc.

OPKO Health, Inc.

Prolong Pharmaceuticals, LLC

VisusMed Medical Center

Boston Pharmaceuticals, Inc

Report Scope:

In this report, the Global Synthetic Blood Substitute Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Blood Substitute Market, By Product:

    Hemoglobin-Based Oxygen Carriers (HBOCs) Perfluorocarbon Emulsions (PFCs) Stem Cell-Derived Red Blood Cells Others

Synthetic Blood Substitute Market, By Application:

    Cardiovascular Diseases Malignant Neoplasma Injuries Neonatal Conditions Organ Transplant Maternal Condition Others

Synthetic Blood Substitute Market, By Source:

    Human Blood Microorganism Based Recombinant HB Synthetic Polymers Stem Cells Others

Synthetic Blood Substitute Market, By Component:

    Red Blood Cell Substitutes Platelet Substitutes Plasma Substitutes

Synthetic Blood Substitute Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Blood Substitute Market.

Available Customizations:

Global Synthetic Blood Substitute market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Synthetic Blood Substitute Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Hemoglobin-Based Oxygen Carriers (HBOCs), Perfluorocarbon Emulsions (PFCs), Stem Cell-Derived Red Blood Cells, Others)
    • 5.2.2. By Application (Cardiovascular Diseases, Malignant Neoplasma, Injuries, Neonatal Conditions, Organ Transplant, Maternal Condition, Others)
    • 5.2.3. By Source (Human Blood, Microorganism Based Recombinant HB, Synthetic Polymers, Stem Cells, Others)
    • 5.2.4. By Component (Red Blood Cell Substitutes, Platelet Substitutes, Plasma Substitutes)
    • 5.2.5. By Company (2023)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Synthetic Blood Substitute Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Source
    • 6.2.4. By Component
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Synthetic Blood Substitute Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Source
        • 6.3.1.2.4. By Component
    • 6.3.2. Mexico Synthetic Blood Substitute Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Source
        • 6.3.2.2.4. By Component
    • 6.3.3. Canada Synthetic Blood Substitute Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Source
        • 6.3.3.2.4. By Component

7. Europe Synthetic Blood Substitute Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Source
    • 7.2.4. By Component
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Synthetic Blood Substitute Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Source
        • 7.3.1.2.4. By Component
    • 7.3.2. Germany Synthetic Blood Substitute Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Source
        • 7.3.2.2.4. By Component
    • 7.3.3. United Kingdom Synthetic Blood Substitute Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Source
        • 7.3.3.2.4. By Component
    • 7.3.4. Italy Synthetic Blood Substitute Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Source
        • 7.3.4.2.4. By Component
    • 7.3.5. Spain Synthetic Blood Substitute Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Source
        • 7.3.5.2.4. By Component

8. Asia-Pacific Synthetic Blood Substitute Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Source
    • 8.2.4. By Component
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Synthetic Blood Substitute Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Source
        • 8.3.1.2.4. By Component
    • 8.3.2. India Synthetic Blood Substitute Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Source
        • 8.3.2.2.4. By Component
    • 8.3.3. South Korea Synthetic Blood Substitute Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Source
        • 8.3.3.2.4. By Component
    • 8.3.4. Japan Synthetic Blood Substitute Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Source
        • 8.3.4.2.4. By Component
    • 8.3.5. Australia Synthetic Blood Substitute Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Source
        • 8.3.5.2.4. By Component

9. South America Synthetic Blood Substitute Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Source
    • 9.2.4. By Component
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Synthetic Blood Substitute Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Source
        • 9.3.1.2.4. By Component
    • 9.3.2. Argentina Synthetic Blood Substitute Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Source
        • 9.3.2.2.4. By Component
    • 9.3.3. Colombia Synthetic Blood Substitute Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Source
        • 9.3.3.2.4. By Component

10. Middle East and Africa Synthetic Blood Substitute Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Source
    • 10.2.4. By Component
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Synthetic Blood Substitute Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Source
        • 10.3.1.2.4. By Component
    • 10.3.2. Saudi Arabia Synthetic Blood Substitute Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Source
        • 10.3.2.2.4. By Component
    • 10.3.3. UAE Synthetic Blood Substitute Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Source
        • 10.3.3.2.4. By Component

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Aurum Biosciences Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Hemarina SA
  • 14.3. Hemoglobin Oxygen Therapeutics LLC
  • 14.4. SpheriTech Ltd
  • 14.5. Kalocyte, Inc.
  • 14.6. OPKO Health, Inc.
  • 14.7. Prolong Pharmaceuticals, LLC
  • 14.8. VisusMed Medical Center
  • 14.9. Boston Pharmaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer